Brokerage firm Morgan Stanley Maintains its rating on Alexion Pharmaceuticals(NASDAQ:ALXN). In a research note issued to the investors, the brokerage major Lowers the price-target to $189.00 per share. The shares have been rated Overweight. The rating by Morgan Stanley was issued on Jun 7, 2016.
In a different note, On Apr 29, 2016, BMO Capital said it Upgrades its rating on Alexion Pharmaceuticals. The shares have been rated ‘Outperform’ by the firm. BMO Capital said it Initiates Coverage on Alexion Pharmaceuticals, according to a research note issued on Apr 7, 2016. The shares have been rated ‘Market Perform’ by the firm.
Alexion Pharmaceuticals (ALXN) shares turned negative on Fridays trading session with the shares closing down -2.63 points or -1.90% at a volume of 19,83,755. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $137.86. The peak price level was also seen at $137.86 while the days lowest was $134.02. Finally the shares closed at $135.61. The 52-week high of the shares is $208.88 while the 52-week low is $124.16. According to the latest information available, the market cap of the company is $30,379 M.
Alexion Pharmaceuticals(ALXN) last announced its earnings results on Apr 28, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $701.04M. Analysts had an estimated revenue of $710.98M. Earnings per share were $1.11. Analysts had estimated an EPS of $1.13.
Several Insider Transactions has been reported to the SEC. On May 18, 2016, Martin Mackay (EVP & Global Head of R&D) sold 4,097 shares at $139.81 per share price.Also, On May 13, 2016, Heidi L Wagner (SVP, Global Government Affairs) sold 53 shares at $138.65 per share price.On Apr 5, 2016, David Hallal (CEO) sold 1,414 shares at $136.04 per share price, according to the Form-4 filing with the securities and exchange commission.
Alexion Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23 2015 the Company had eight product candidates in clinical trials for 11 indications. The Company’s product pipeline includes complement inhibitor portfolio metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris ALXN1007 ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq Kanuma ALXN1101 and SBC-103. The Company’s preclinical candidates include mRNA Therapies SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) two life-threatening ultra-rare disorders.